| 31st week of 2022 patent applcation highlights part 9 |
| Patent application number | Title | Published |
|---|
| 20220241229 | Methods and Compositions for Altering Senescence Associated Secretory Phenotype - Disclosed herein are methods and compositions comprising alpha ketoglutarate (AKG) for altering senescence-associated secretory phenotype (SASP), and related diseases. | 2022-08-04 |
| 20220241230 | DICLOFENAC SACHET COMPOSITION - A pharmaceutical composition for oral administration comprising a free-flowing granular powder comprising diclofenac or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable substantially non-hygroscopic water soluble diluent, an optional binder, and one or more optional pharmaceutically acceptable excipients, wherein the composition is devoid of any alkalizer, buffer or base. The pharmaceutical composition is divided into unit doses containing a therapeutically effective amount of diclofenac, and may be incorporated into sachets, tablets or capsules. and not less than 85% of the free-flowing granulate powder dissolves after 3 minutes in simulated intestinal fluid at pH 6.8. The pharmaceutical composition is rapidly bioavailable when orally administered to a mammal, e.g., human. | 2022-08-04 |
| 20220241231 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS - The present disclosure relates to pharmaceutical compositions for treating cognitive decline in companion animals, comprising a 5-benzylaminosalicylic acid compound of formula (I), or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient, e.g., suitable for oral administration. Compositions comprising the 5-benzylamino salicylic acid compound of formula (I), or a pharmaceutically acceptable salt thereof can be used to treat progressive cognitive disorder in neurological diseases including cognitive dysfunction syndrome (CDS), dysthymia, involutive depression, and confusional syndrome in aging companion animals. | 2022-08-04 |
| 20220241232 | METHOD FOR TREATMENT OF AT RISK PATIENTS - The invention provides an anti-fibrotic or anti-nonalcoholic steatohepatitis (NASH) drug for use in a method for reducing the risk for a subject to develop liver fibrosis or NASH, wherein the drug is administered to a subject classified as at risk to develop liver fibrosis or NASH. The invention further provides an anti-fibrotic or anti-NASH substance for use in a method for the treatment of liver fibrosis or NASH, wherein the drug is administered to a subject having type 2 diabetes. | 2022-08-04 |
| 20220241233 | 5,6-DIHETE LACTONE FOR TREATMENT OF MICROVASCULAR DYSFUNCTION - The present invention provides 5,6 dihydroxyeicosatetraenoic acid (5,6-diHETE) lactone or a pharmaceutical composition comprising 5,6-diHETE lactone and a pharmaceutically acceptable carrier, and uses thereof for inducing vasodilation, for treating a disease, disorder or condition associated with microvascular dysfunction, or for preventing, or reducing the risk of, developing a cardiac condition associated with microvascular dysfunction. | 2022-08-04 |
| 20220241234 | METHODS OF TREATING MIXED DYSLIPIDEMIA - The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate. | 2022-08-04 |
| 20220241235 | COMPOSITION COMPRISING CITRATE AND CARNITINE ABLE TO ACTIVATE THE PRODUCTION OF THE PROTEIN KLOTHO - A composition comprising citrate and carnitine which activates the production of the protein Klotho by renal tubule cells protecting them, thus reducing the oxidative stress conditions thereof, which can be used for the conservation, perfusion and reperfusion of organs for organ transplants is disclosed. Furthermore, the composition in the liquid and dietary/nutraceutical formulation can be used for reducing the nephrotoxicity induced by iodinated contrast means, antibiotics, NSAIDs | 2022-08-04 |
| 20220241236 | DIETARY BUTYRATE AND ITS USES - 1. Use of a compound having the formula (1) (2) (3) or (4) or combinations thereof, for use in promotion of bone growth and/or prevention and/or treatment of bone disorders associated to bone growth impairment wherein R | 2022-08-04 |
| 20220241237 | COMPOSITION FOR TREATING DEGENERATIVE BRAIN DISEASES, CONTAINING 2-PENTYLFURAN AS ACTIVE INGREDIENT - The present invention relates to a composition for preventing or treating a degenerative brain disease, comprising 2-pentylfuran or a solvate thereof, a stereoisomer thereof or a pharmaceutically acceptable salt thereof as an active ingredient. | 2022-08-04 |
| 20220241238 | METHOD FOR FORMING A BEVERAGE WITH A DISSOLVABLE THC TABLET - The invention comprises a method and apparatus for forming a beverage, comprising the steps of: dissolving a tablet in the beverage, the tablet containing tetrahydrocannabinol; forming gas bubbles, such as carbon dioxide, within the beverage through a chemical reaction; and mixing the tetrahydrocannabinol in the beverage through motion of the gas bubbles, such as where the tetrahydrocannabinol is maintained, after the step of mixing, in suspension in the beverage for a period of at least five minutes through at least movement of the gas bubbles. | 2022-08-04 |
| 20220241239 | PHARMACEUTICAL COMPOSITION FOR SUBCUTANEOUS ADMINISTRATION - This application concerns pharmaceutical compositions comprising cannabinoids which are suitable for subcutaneous administration in human subjects. Thus, this application concerns pharmaceutical compositions for subcutaneous administration. The pharmaceutical compositions according to the invention are particularly suitable for subcutaneous administration, which is advantageous for improving bioavailability and reducing toxicity. | 2022-08-04 |
| 20220241240 | AGENTS AND METHODS FOR INCREASING STEM CELL FUNCTION - Use of a urolithin for increasing stem cell function in a population of haematopoietic stem and/or progenitor cells (HSPCs). | 2022-08-04 |
| 20220241241 | OXALAMIDO-SUBSTITUTED TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS - The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing the compounds. | 2022-08-04 |
| 20220241242 | ENZYMATIC PROCESS FOR THE PREPARATION OF (2S)-2-[(4R)-2-OXO-4-PROPYL-PYRROLIDIN-1-YL]BUTYRIC ACID AND ITS CONVERSION INTO BRIVARACETAM - A process for the preparation of Brivaracetam, an anti-convulsion drug, is provided comprising enzymatic conversion of (2RS)-2-[ (4R)-2-oxo-4-propyl-pyrrolidin-1-yl] butyric acid methyl ester selectively into (2S)-2-[ (4R)-2-oxo-4-propyl-pyrrolidin-1-yl] butyric acid having high chiral purity, using protease from | 2022-08-04 |
| 20220241243 | METHODS OF TREATING MOOD DISORDERS - Methods of treating mood disorders with compounds disclosed herein. Also provided are pharmaceutical compositions that include those compounds. | 2022-08-04 |
| 20220241244 | Method and Composition for Treating Seizure Disorders - A composition for treating seizure disorders such as epilepsy comprises (i) an anticonvulsant drug of the hydantoin family; (ii) phytocannabinoid cannabidiol (CBD); and (iii) a fat-soluble vitamin. | 2022-08-04 |
| 20220241245 | PRESBYOPIA TREATMENTS - Described herein are methods and compositions for the treatment of ocular conditions and for the improvement of vision parameters using pharmaceutically acceptable ophthalmic pilocarpine formulations. A nonlimiting example of an ocular condition that may be treated with the methods and compositions disclosed herein is presbyopia. | 2022-08-04 |
| 20220241246 | METHODS OF USE FOR TRISUBSTITUTED BENZOTRIAZOLE DERIVATIVES AS DIHYDROOROTATE OXYGENASE INHIBITORS - The present invention provides methods for treating a cancer in a subject and for inhibiting tumor growth, metastasis or a dihydrorotate oxygenase enzyme activity of a tumor or cancer cell. At least one trisubstituted benzotriazole derivative with the formula (I) is administered to the subject or is contacted with the cancer cell. Compounds of formula (I) have substituents R | 2022-08-04 |
| 20220241247 | PHARMACOLOGICAL AGENTS FOR TREATING PROTEIN AGGREGATION DISEASES OF THE EYE - Methods of treating presbyopia or cataract in a subject in need thereof are provided. The methods require administering to the subject an effective amount of a composition comprising a compound that inhibits the formation of high molecular weight aggregates of human α-A-crystallin. A method of preventing and/or treating transthyretin (TTR)-associated amyloidosis using certain of these compounds is also provided. | 2022-08-04 |
| 20220241248 | COMBINATION OF SMALL MOLECULE CD-47 INHIBITORS WITH OTHER ANTI-CANCER AGENTS - The present invention relates to a composition of a CD47-SIRPα blocking agent and one or more anti-cancer agent(s), where the CD47-SIRPα blocking agents are represented by a compound of formula (I). The present invention also relates to a method of treating a cancer in a subject by administering a therapeutically effective amount of a CD47-SIRPα blocking agent represented by formula (I) in combination with one or more anti-cancer agent(s). | 2022-08-04 |
| 20220241249 | PHARMACEUTICAL COMPOSITION AND KIT CONTAINING NOVEL PENAM DERIVATIVE OR SALT THEREOF AND ONE OR MORE COMPOUNDS SELECTED FROM beta-LACTAMASE INHIBITORY COMPOUND AND ANTIBACTERIAL COMPOUND OR SALTS THEREOF - An object of the present invention is to provide a pharmaceutical composition and a kit which exhibit strong antibacterial activity against Gram-negative bacteria and/or drug-resistant Gram-negative bacteria. | 2022-08-04 |
| 20220241250 | LIQUID TOPICAL PREPARATION - What is aimed at is to provide a topical preparation that contains tacrolimus as an active pharmaceutical ingredient, has high stability and transdermal absorbability of the active pharmaceutical ingredient, is less irritating, and has a good feeling of use. The present invention relates to a liquid topical preparation that contains (i) tacrolimus, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and (ii) at least one ketone, and that is substantially free of ethanol. It is preferable that the liquid topical preparation further contains at least one fatty acid ester and fluid paraffin, and is substantially free of water. | 2022-08-04 |
| 20220241251 | STABILISATION AND CONTROLLED-RELEASE SYSTEMS FOR MEDICAMENTS UNSTABLE ON STERILISATION - Disclosed are alkenylamides of sulfated hyaluronic acid and their use for the stabilisation and release of medicaments in the form of micellar suspensions which can be administered locally and/or locoregionally, in particular intra-articularly. | 2022-08-04 |
| 20220241252 | METHODS OF TREATING CHEMICAL GAS EXPOSURE - A method of treating chemical-induced lung injury in a subject in need thereof includes administering to the subject a therapeutically effective amount of ibudilast, or a pharmaceutical salt thereof. | 2022-08-04 |
| 20220241253 | USE OF GABOXADOL IN THE TREATMENT OF SUBSTANCE USE DISORDERS - Methods of using gaboxadol or a pharmaceutically acceptable salt thereof and compositions of gaboxadol or a pharmaceutically acceptable salt thereof for use in treating a substance use disorder, preventing a substance use craving, diminishing a substance use craving, and/or facilitating substance use cessation are provided. Substance use disorders include alcohol use disorder, caffeine use disorder, cannabis use disorder, hallucinogen use disorder, inhalant use disorder, opioid use disorder, sedative use disorder, stimulant use disorder, tobacco use disorder and nicotine use disorder. | 2022-08-04 |
| 20220241254 | FIXED DOSE COMBINATION OF CHOLINESTERASE INHIBITOR AND A QUATERNARY AMMONIUM ANTIMUSCARINIC AGENT TO TREAT NEURODEGENERATIVE COGNITIVE DISORDERS - The present invention includes a method for improving cognitive function in a human suffering from a neurodegenerative cognitive disorder. The method comprises administering to a patient a total daily dose of a cholinesterase inhibitor and a quaternary ammonium antimuscarinic compound. The total daily dose is divided into one or more doses administered before food intake. The quaternary ammonium antimuscarinic compound is administered in a first drug delivery element configured for rapid absorption into a body of the patient, and the cholinesterase inhibitor is administered in a second drug delivery element configured for a slower or delayed absorption into the body of the patient. | 2022-08-04 |
| 20220241255 | COMBINATION CONTAINING SGC ACTIVATORS AND MINERALOCORTICOID RECEPTOR ANTAGONISTS - The present invention relates to the combination of activators of soluble guanylate cyclase (sGC activators) with mineralocorticoid receptor antagonists (MR antagonists) and to the use of the combination for the treatment and/or prophylaxis of cardiac and cardiovascular disorders, of renal and cardiorenal disorders, of pulmonary and cardiopulmonary disorders and also for the treatment and/or prophylaxis of fibrotic disorders. | 2022-08-04 |
| 20220241256 | METHODS OF TREATING GASTROINTESTINAL STROMAL TUMORS - The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof. | 2022-08-04 |
| 20220241257 | Sorafenib particles and uses thereof - The disclosure provides particles of at least 95% by weight of sorafenib, or a pharmaceutically acceptable salt thereof, wherein the particles have a specific surface area (SSA) of at least 2 m | 2022-08-04 |
| 20220241258 | FORMULATIONS OF T-TYPE CALCIUM CHANNEL MODULATORS AND METHODS OF USE THEREOF - Described herein, in part, are dosage forms and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a T-type calcium channel, such as epilepsy and epilepsy syndromes (e.g., absence seizures, juvenile myoclonic epilepsy, or a genetic epilepsy), tremor (e.g., essential tremor), and psychiatric disorder (e.g., mood disorders (e.g., major depressive disorder)). The present invention further comprises methods for modulating the function of a T-type calcium channel. | 2022-08-04 |
| 20220241259 | COMPOSITIONS AND METHODS USING TRIGONELLINE AND VITAMINS FOR PREVENTING OR TREATING CONDITIONS OR DISORDERS IN SKELETAL MUSCLE - The present invention relates to compositions and methods for preventing or treating skeletal muscle conditions or diseases. The present invention also relates to compositions and methods that help to increase NAD+ levels in skeletal muscle. Preferably, the present invention relates to compositions and methods that use trigonelline and vitamins selected from the group consisting of: Vitamin D, Vitamin B12, B3, B6, B7, Vitamin C and/or Vitamin E for preventing or treating skeletal muscle conditions or diseases. The recipient of the compositions of the invention can be, for example, an elderly individual or an individual with sarcopenia or an individual in need of the compositions and methods of the invention for recovery of skeletal muscles, for example, after exercise, muscle injury or surgery. | 2022-08-04 |
| 20220241260 | Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) Antagonists - Pharmaceutical compositions of metabotropic glutamate 5 receptor (mGlu5) antagonists or a pharmacologically acceptable salt thereof are disclosed. The compositions contain the therapeutic active compound with non-ionic polymer and ionic polymer, binder and fillers in either matrix pellet, matrix tablet or coated pellets. The compositions provide a pH-independent in vitro release profile with NMT 70% in one hour, NMT 85% in 4 hour, and NLT 80% in 8 hours. The compositions are useful for the treatment of CNS disorders, such as Treatment-Resistant Depression (TRD) and Fragile X Syndrome. | 2022-08-04 |
| 20220241261 | COMBINATIONS OF INHIBITORS OF IRAK4 WITH INHIBITORS OF BTK - The present application relates to novel combinations of at least two components, component A and component B:
| 2022-08-04 |
| 20220241262 | DIHYDROPYRIDINE COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS - The present disclosure provides extended or sustained release compositions of a dihydropyridine calcium channel blocker, specifically isradipine, and method of using said compositions for the treatment of neurological disorders, wherein the composition provides sustained plasma levels of the dihydropyridine calcium channel blocker. | 2022-08-04 |
| 20220241263 | PD-1 AXIS BINDING ANTAGONIST TO TREAT CANCER WITH GENETIC MUTATIONS IN SPECIFIC GENES - The present disclosure describes combination therapies comprising a PD-1 axis binding antagonist, wherein the cancer has been pre-determined to have one or more genetic mutations in one or more genes, to have certain gene expression profiles, and/or to have other biomarkers. | 2022-08-04 |
| 20220241264 | METHODS FOR PREVENTION AND TREATMENT OF FIBROMYALGIA BY CONTACT VASODILATORS - Methods are provided to prevent and to treat fibromyalgia by using a vasodilator such as an angiotensin receptor blocker, ACE inhibitor, calcium channel blocker, phosphodiesterase inhibitor, alpha blocker, or beta blocker. More particularly, the methods do not employ orally administered vasodilators, but instead vasodilators that are administered through contact with the epidermis, e.g., in topical or other form suitable for contact with tissues to be treated. The compositions promote neo capillary formation, whereby symptoms of fibromyalgia are treated, reduced, or ameliorated. | 2022-08-04 |
| 20220241265 | SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR NEURODEGENERATIVE DISEASES - Behavioral pharmacological data with the compound of formula (1), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that SHT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis. | 2022-08-04 |
| 20220241266 | COMPOSITIONS AND METHODS USING TRIGONELLINE AND HIGH PROTEIN FOR PREVENTING OR TREATING CONDITIONS OR DISORDERS IN SKELETAL MUSCLE - The present invention relates to compositions and methods for preventing or treating skeletal muscle conditions or diseases. The present invention also relates to compositions and methods that help to increase levels of NAD+ in skeletal muscle. Preferably, the present invention relates to compositions and methods that use trigonelline, high protein and/or creatine and/or tryptophan for preventing or treating skeletal muscle conditions or diseases. The recipient of the compositions or methods of the invention can be, for example, an elderly individual or an individual with sarcopenia or an individual in need of the compositions and methods of the invention for recovery of skeletal muscles, for example, after exercise, muscle injury or surgery. | 2022-08-04 |
| 20220241267 | BISAMINOQUINOLINES AND BISAMINOACRIDINES COMPOUNDS AND METHODS OF THEIR USE - The disclosure is directed to bisaminoquinolines and bisaminoacridines as autophagy inhibitors for treating cancer and other disease states and conditions. | 2022-08-04 |
| 20220241268 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT DRUG OVERDOSE - Methods and compositions are provided for treating individuals exhibiting opioid withdrawal symptoms with opioid, benzodiazepine and other drugs of abuse by administering an opioid receptor antagonist agent together with a respiratory stimulant to reverse the effects of opioid withdrawal symptoms, including respiratory depression, sedation, and hypotension. Methods and compositions are also provided for treating stimulant overdose with a benzodiazepine and beta-adrenergic blocking agent. Methods and compositions are also provided for treating concurrent stimulant and opioid overdose comprising administering to a patient in need thereof a benzodiazepine and an opioid antagonist. Methods and compositions are also provided for treating individuals exhibiting opioid withdrawal symptoms or prophy tactically treating individuals for opioid withdrawal symptoms from opioid, benzodiazepine and other drugs of abuse by administering an opioid receptor antagonist agent together with a respiratory stimulant to reverse the effects of withdrawal, including respiratory depression, sedation, and hypotension. | 2022-08-04 |
| 20220241269 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY - Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan. | 2022-08-04 |
| 20220241270 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY - Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan. | 2022-08-04 |
| 20220241271 | INHALABLE DRY POWDERS - The present disclosure relates to inhalable dry powder compositions comprising cannabinoids. In particular, the formulations are intended for use with dry powder inhalers for single use or multiple use comprising replaceable cartridges for delivery to the deep lung as medicinal agents. The inhalable dry powders are useful in the treatment of diseases and disorders, including pain. | 2022-08-04 |
| 20220241272 | METHODS OF TREATING FIBROSIS USING COMPOUNDS THAT PROMOTE GLUCOSE OXIDATION - The invention provides methods for treating or preventing fibrosis in a subject by providing a compound that shifts cellular metabolism from fatty acid oxidation to glucose oxidation. | 2022-08-04 |
| 20220241273 | USE OF SGC ACTIVATORS FOR THE TREATMENT OF OPHTHALMOLOGIC DISEASES - The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of ophthalmologic diseases, including non-proliferative diabetic retinopathy (NPDR), diabetic macular edema (DME), retinal ganglion cell/photoreceptor neurodegeneration and cataract. | 2022-08-04 |
| 20220241274 | CANNABINOID RECEPTOR MODULATORS - Provided are certain methods useful in the treatment of pain comprising administering a compound of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB | 2022-08-04 |
| 20220241275 | TARGETED TREATMENT OF CANCERS WITH DYSREGULATED FIBROBLAST GROWTH FACTOR RECEPTOR SIGNALING - The present invention provides advantageous methods and compositions for treating a host having a cancer with dysregulation of the FGFR signaling pathway, which includes administering an effective amount of a selective CDK4/6 inhibitor described herein in combination or alternation with a fibroblast growth factor receptor inhibitor. | 2022-08-04 |
| 20220241276 | COMPOSITIONS AND METHODS FOR TREATING CANCER - The present disclosure relates to compositions, systems, and methods for treating cancer. In particular, the present disclosure relates to compositions, systems, and methods for utilizing gene expression and methylation profiles to stratify and treat adrenocortical carcinoma and drugs which have utility for patients stratified by these means. | 2022-08-04 |
| 20220241277 | PHARMACEUTICAL COMBINATION COMPRISING AN ALK INHIBITOR AND A SHP2 INHIBITOR - A pharmaceutical combination comprising an ALK inhibitor, in free form or a pharmaceutically acceptable salt thereof, and a SHP2 inhibitor, in free form or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, for simultaneous or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination. | 2022-08-04 |
| 20220241278 | INHALABLE IMATINIB FORMULATION - Pharmaceutical compositions comprising imatinib or a derivative thereof for treatment of a pulmonary disease via inhalation. Methods of treating a pulmonary disease include administering by inhalation an effective amount of imatinib or a derivative thereof to a patient in need thereof. In aspects, the pharmaceutical composition provided herein comprises an aqueous solution or suspension of imatinib or a derivative thereof that is formulated for inhalatory administration. | 2022-08-04 |
| 20220241279 | PHARMACEUTICAL COMPOSITIONS COMPRISING AKT PROTEIN KINASE INHIBITORS - The present invention relates to pharmaceutical compositions comprising Akt protein kinase inhibitors with therapeutic activity against diseases such as cancer as well as processes for their preparation and their use as medicament. | 2022-08-04 |
| 20220241280 | PHARMACEUTICAL COMPOSITION AND THERAPEUTIC METHOD FOR TREATING FGFR1 VARIANT-POSITIVE BRAIN TUMOR - The present invention provides a pharmaceutical composition for treating a patient with an FGFR1 mutant-positive brain tumor, the composition comprising (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one or a pharmaceutically acceptable salt thereof as an active ingredient; and a therapeutic method using the pharmaceutical composition. | 2022-08-04 |
| 20220241281 | Imidazopyrimidine Derivatives - The present disclosure provides a compound of Formula (I): | 2022-08-04 |
| 20220241282 | PAR1 MODULATION TO ALTER MYELINATION - Materials and methods for modulating protease activated receptor 1 (PAR1) activity to alter myelination are provided. | 2022-08-04 |
| 20220241283 | METHOD FOR PRODUCING ALGINIC ACID-FOLIC ACID CONJUGATE, ALGINIC ACID-FOLIC ACID CONJUGATE PRODUCED THEREBY AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME - The present invention relates to a method for producing an alginic acid-folic acid conjugate, an alginic acid-folic acid conjugate produced thereby, and a pharmaceutical composition containing the same. According to the method of producing an alginic acid-folic acid conjugate using a carboxy-protecting group and a leaving group, the hydroxyl group of alginic acid forms an ester group with the carboxyl group of folic acid. Thus, the alginic acid-folic acid conjugate may clearly distinguish cancer cells from normal tissue by more effectively targeting cancer cells than a conventional alginic acid-conjugated folic acid in which the amine group of folic acid is covalently bonded to the carboxyl group of alginic acid. Accordingly, the alginic acid-folic acid conjugate may be effectively used for precise diagnosis and efficient surgical resection of cancer lesions. | 2022-08-04 |
| 20220241284 | TREATMENT OF CUTANEOUS LUPUS ERYTHEMATOSUS - The present invention relates to the treatment of cutaneous lupus erythematosus. The problem to be solved by the invention is to provide a new pharmaceutical use of 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile, a therapeutic or preventive agent cutaneous lupus erythematosus, containing 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile as an active ingredient, and a pharmaceutical formulation thereof. | 2022-08-04 |
| 20220241285 | ORAL CAPSULE AND PREPARATION METHOD THEREFOR - An oral capsule and a method for filling a capsule after directly mixing powders, the oral capsule comprising a composition for the oral capsule and a capsule shell, the composition for the oral capsule comprising zanubrutinib, a filler, a disintegrant, a wetting agent, a glidant, a lubricant, and optionally a binder. The composition for the capsule is capable of obtaining satisfactory product stability, dissolution properties that meet bioavailability standards, a preparation process consistent with production equipment, and reasonable production costs. In addition, the method is a non-granulating process, which may simplify the overall process steps and reduce the impact of the preparation process on product bioavailability. | 2022-08-04 |
| 20220241286 | TREATMENT OF HIDRADENITIS SUPPURATIVA USING JAK INHIBITORS - The present application provides methods of treating hidradenitis suppurativa in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound which inhibits JAK1 and/or JAK2, or a pharmaceutically acceptable salt thereof. | 2022-08-04 |
| 20220241287 | COMBINATION THERAPIES - Provided herein are pharmaceutical compositions comprising a phosphatidylinositol 3-kinase inhibitor, or pharmaceutically acceptable form thereof, in combination with a second agent, or a pharmaceutically acceptable form thereof, wherein the second agent is chosen from one or more of 1) a checkpoint modulator, 2) an XPO1 inhibitor, 3) an anti-CD19 antibody, 4) a TLR agonist, 5) a STING agonist, or 6) a Flt3 ligand, or a combination thereof. Also provided herein are methods of treatment comprising administration of the compositions, and uses of the compositions, e.g., for treatment of cancer. | 2022-08-04 |
| 20220241288 | COMPOSITIONS AND METHOD OF TREATING CANCER - The disclosure provides for methods and compositions useful for treating infections, cancer and neoplastic diseases and disorders. | 2022-08-04 |
| 20220241289 | STIMULANT COMPOSITION AND PROCESS FOR MAKING SAME - A liquid composition for use as a consumable stimulant; it has a consumable liquid solvent comprising water; caffeine at a concentration of at least 0,04 g/mL once dissolved in the consumable liquid solvent; and a tyrosine-based compound, wherein the presence of the tyrosine-based compound results in an increased solubility of the caffeine in the consumable liquid solvent. A method of increasing the solubility of caffeine. | 2022-08-04 |
| 20220241290 | METHODS OF TREATING SOLID TUMORS WITH CCR2 ANTAGONISTS - The present disclosure provides, inter alia, methods of treating a solid-tumor by administering an effective amount of a Chemokine Receptor 2 (CCR2) antagonist. Also provided herein are methods of reducing the number of macrophages in a solid tumor microenvironment, said method comprising administering effective amount of a Chemokine Receptor 2 (CCR2) antagonist. In an additional aspect, the current disclosure further provides methods of increasing the number CD8+ T cells in a solid tumor microenvironment, said method comprising administering effective amount of a Chemokine Receptor 2 (CCR2) antagonist. In some embodiments, the CCR2 antagonist has the formula I: | 2022-08-04 |
| 20220241291 | OXYGEN LINKED PYRIMIDINE DERIVATIVES - The present invention relates to pyrimidine compounds that are useful as anti-proliferative agents. More particularly, the present invention relates to oxygen linked and substituted pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative disorders including tumours and cancers as well as other disorders or conditions related to or associated with kinases. | 2022-08-04 |
| 20220241292 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM - Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T | 2022-08-04 |
| 20220241293 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE - An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug. | 2022-08-04 |
| 20220241294 | BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS FOR TREATING NOTCH-ACTIVATED BREAST CANCER - The present invention provides methods of reducing tumor size, suppressing or inhibiting tumor growth, or prolonging progression-free survival or overall survival in subjects having Notch-activated breast cancer by administering compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (III): or prodrugs thereof, alone or in combination with a composition comprising a cytotoxic agent. Notch-activated breast cancer may be determined by a) Notch-activating genetic alterations in one or more Notch genes, b) overexpression of one or more Notch-regulated genes, c) overexpression of one or more Notch proteins or Notch-regulated proteins, or a combination thereof. | 2022-08-04 |
| 20220241295 | PHARMACEUTICAL COMPOSITION CONTAINING BREXANOLONE, GANAXOLONE, OR ZURANOLONE, AND USE THEREOF - Disclosed herein is a pharmaceutical composition comprising a pharmaceutically effective amount of a neuroactive steroid that is a positive modulator of γ aminobutyric acid type A (GABA | 2022-08-04 |
| 20220241296 | PROCESS FOR THE PREPARATION OF STERILE OPHTHALMIC AQUEOUS FLUTICASONE PROPIONATE FORM A NANOCRYSTALS SUSPENSIONS - The present invention relates to an improved process of manufacturing sterile topical ophthalmic aqueous nanosuspensions of nanocrystals of fluticasone propionate Form A. The sterile topical ophthalmic nanosuspensions are useful in the treatment of eye inflammation conditions such as blepharitis, posterior blepharitis, Meibomian gland dysfunction and dry eye through topical administration of said nanosuspensions to eyelids, eyelashes and eyelid margin. | 2022-08-04 |
| 20220241297 | USE OF CICLESONIDE FOR THE TREATMENT OF RESPIRATORY DISEASES - Disclosed herein are novel methods of treating respiratory diseases, and in particular the treatment of asthmatic children. | 2022-08-04 |
| 20220241298 | ORAL COMPOSITION OF CELECOXIB FOR TREATMENT OF PAIN - The present invention relates to a stable oral liquid pharmaceutical composition of celecoxib or its pharmaceutically acceptable salts thereof. The celecoxib present in the compositions as described herein do not show any precipitation when subjected in Fasted-State Simulated Gastric Fluid (FaSSGF) at pH 2.0, temperature of 37° C.±0.5° C. and under stirring at a speed of 50 rpm at least for 60 minutes. It also relates to the process of preparing and method of using said composition of celecoxib. | 2022-08-04 |
| 20220241299 | GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS - The disclosure provides compounds having formula (I): | 2022-08-04 |
| 20220241300 | NEXT GENERATION REMDESIVIR ANTIVIRALS - The disclosure relates to compounds of the formula (I) and (II), pharmaceutical compositions comprising one or more such compounds, and methods for treating pulmonary infections with one or more such compounds (e.g., treating SARS-CoV, MERS-CoV or SARS-CoV-2). | 2022-08-04 |
| 20220241301 | COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND - The present disclosure relates to compositions and methods for inhibiting inflammation and reducing the risk of spreading sexually transmitted diseases using an alginic acid-based antimicrobial compound. Such compositions provide dual protection by (1) attacking and inactivating viruses and other microbes and (2) blocking the host response that viruses trigger to invade host cells. Such compositions can also be part of an acid buffering contraceptive. | 2022-08-04 |
| 20220241302 | Surfactant Lipids, Compositions Thereof, and Uses Thereof - The invention generally relates to methods to inhibit inflammation or pathogen infection by administering at least one anionic lipid or compositions comprising at least one anionic lipid to an individual. The invention also relates to methods to prevent or inhibit respiratory syncytial virus (RSV) infection by administering at least one anionic lipid or compositions comprising at least one anionic lipid to an individual. The invention further relates to compositions comprising randomly mixed surfactant lipids and methods to produce the compositions. | 2022-08-04 |
| 20220241303 | METHODS OF TREATING ACUTE CORONARY SYNDROMES - The invention provides methods for treating and preventing acute coronary syndromes (ACS). The methods involve initiation of the administration of glucose-insulin-potassium (GIK) soon (e.g., within 3 hours) after the onset of ACS symptoms. | 2022-08-04 |
| 20220241304 | SUBLINGUAL DELIVERY OF ANTI-VIRAL AGENTS AND CB2 RECEPTOR AGONISTS - A device is provided for treating inflammation, viral infection, and infectious disease conditions. The device includes a sublingual delivery film, dissolvable powder, compressed tablet, or tincture, with an ACE2 receptor binding competitor and a CB2 receptor agonist that could include cannabichromene. A composition is also provided to treat inflammation, viral infection, or infectious disease. The composition includes an ACE2 receptor binding competitor and a CB2 receptor agonist. A method is also provided for treating inflammation, viral infection, or infectious disease, including applying a sublingual delivery film, dissolvable powder, compressed tablet, or tincture, with an ACE2 receptor binding competitor and a CB2 receptor agonist. A composition for treating a patient with inflammation, viral infection and/or infectious disease is also provided, including an ACE2 receptor binding competitor and a CB2 receptor agonist. | 2022-08-04 |
| 20220241305 | ETHYL CELLULOSE BASED COATINGS FOR MICROENCAPSULATION OF NICOTINAMIDE RIBOSIDE, NICOTINIC ACID RIBOSIDE, REDUCED NICOTINYL RIBOSIDE COMPOUNDS, AND NICOTINYL RIBOSIDE COMPOUND DERIVATIVES - A process is provided for microencapsulating nicotinamide riboside (NR), and other NR derivatives by using ethyl cellulose which may be polymerized in a particular manner. Further, compositions comprising NR or derivatives thereof microencapsulated in an edible biopolymer are provided. | 2022-08-04 |
| 20220241306 | CHITIN ANALOGS FOR THE TREATMENT OF KIDNEY DISEASES - The present invention includes compositions and methods for preventing or treating a patient for kidney injury comprising administering an effective amount of a compound of Formula I: | 2022-08-04 |
| 20220241307 | INHALED IVERMECTIN - The present invention contemplates the use of inhaled ivermectin for use in various viruses and parasitic infections (treatment and/or prophylaxis) that are present or manifest in the lungs or respiratory tract. Exemplary dosing, formulations, devices, and processing techniques are also disclosed herein. | 2022-08-04 |
| 20220241308 | NEURONAL FUNCTION MODULATING AGENT - Provided is a neuronal function modulating agent effective for neuronal cell protection and exerts a neuronal function modulating effect through neuronal cell protection. The disclosed neuronal function modulating agent comprises malvidin-3,5-diglucoside as an active ingredient, the disclosed pharmaceutical composition comprises the neuronal function modulating agent, and the disclosed food composition comprises the neuronal function modulating agent. | 2022-08-04 |
| 20220241309 | THE HSP90 ACTIVATOR AHA1 DRIVES PRODUCTION OF PATHOLOGICAL TAU AGGREGATES - Disclosed herein are compounds and methods for inhibiting Aha1 for the treatment of tauopathies and neurodegenerative diseases. The Aha1 inhibitor may reduce the interaction between Aha1 and Hsp90. The Aha1 inhibitor may reduce aggregation of tau protein. The Aha1 inhibitor may include a compound selected from KU-177, KU-174, and KU-308. | 2022-08-04 |
| 20220241310 | THIARABINE- AND THIARABINE PRODRUG-BASED TREATMENTS - The present disclosure is concerned with combination therapies that include sulfur-based nucleotide and nucleoside compounds for the treatment of various cancers such as, for example, sarcomas, carcinomas, hematological cancers, solid tumors, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, bladder cancer, thyroid cancer, testicular cancer, pancreatic cancer, endometrial cancer, melanomas, gliomas, leukemias, lymphomas, chronic myeloproliferative disorders, myelodysplastic syndromes, myeloproliferative neoplasms, and plasma cell neoplasms (myelomas). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2022-08-04 |
| 20220241311 | METHODS AND MATERIALS FOR TREATING GLYCOSYLATION DISORDERS - This document provides methods and materials involved in treating congenital disorders of glycosylation (CDGs). For example, methods for using a composition including one or more uridine diphosphate (UDP)—sugars to treat a mammal (e.g., a human) having a CDG are provided. | 2022-08-04 |
| 20220241312 | COMPOUNDS FOR TREATING CANCER - Provided herein are prodrugs of 5-fluorodeoxyuridine monophosphate compounds, compositions thereof, methods of their preparation, and their use in treating cancers. In another aspect, provided herein is a pharmaceutical composition comprising any compound disclosed herein, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, diluent, and excipient. | 2022-08-04 |
| 20220241313 | TREATMENT OF ONCOGENE-DRIVEN CANCERS - The present disclosure provides methods of treating a subject identified as having an oncogene driven cancer comprising administering to said subject an agent targeting the extracellular production of adenosine and/or an agent antagonizing the activation by adenosine of one of its receptors. | 2022-08-04 |
| 20220241314 | COMPOSITIONS AND METHODS FOR TREATMENT OF HEPATITIS B VIRUS INFECTION - The disclosure provides compositions and methods for suppressing Hepatitis B virus (HBV) in an infected cell. Exemplary methods comprise contacting the infected cell with one or more agents that induce interferon regulatory factor 3 (IRF3) activation in the infected cell. In some embodiments, the one or more agents comprises pathogen-associated molecular pattern (PAMP)-containing nucleic acid molecule, a small molecule agent (e.g., a benzothiazol-derivative molecule), or a combination thereof. In some embodiments, the method further comprises contacting the infected cell with a NRTI. The method can be an in vivo method of treating a subject with HBV infection, comprising administering therapeutically relevant amounts of one or more agents formulated in one or more therapeutically effect compositions. Exemplary compositions are formulated to treat a hepatitis B virus (HBV) infection in a subject, comprising: a RIG-I agonist, a vehicle for intracellular delivery, and a pharmaceutically acceptable carrier. | 2022-08-04 |
| 20220241315 | THERAPEUTIC AGENT FOR CANCER - An object of the present invention is to provide a nucleic acid medicine for cancer treatment that makes it possible to treat cancer effectively. miR-4711-5p can suppress the expression of KLF5, TFDP1, and MDM2, as a result suppressing the proliferation, infiltration, and migration of cancer cells effectively, inducing apoptosis and G1 arrest, and also lowering stemness. | 2022-08-04 |
| 20220241316 | 25-HYDROXYCHOLESTEROL (25HC), CRYAB AGGREGATION INHIBITOR, IS A NOVEL SENOLYTIC - Methods and compositions are provided herein that pertain to the discovery that the crystallin alpha B (CRYAB) gene and gene product provides an effective target for senolytic agents. In certain embodiments, methods of selectively killing one or more senescent cells in a subject in need thereof are provided wherein the method involves administering to the subject an effective amount of an agent that inhibits expression and/or aggregation of a CRYAB protein. | 2022-08-04 |
| 20220241317 | CONJUGATION OF LIPOPHILIC ALBUMIN-BINDING MOIETY TO RNA FOR IMPROVED CARRIER-FREE IN VIVO PHARMACOKINETICS AND GENE SILENCING - Provided herein are compounds and methods for gene silencing. The compound includes a RNA directly conjugated to an albumin-binding group. The method includes administering a compound comprising a RNA directly conjugated to an albumin-binding group to a subject in need thereof. | 2022-08-04 |
| 20220241318 | ALTERING MICROBIAL POPULATIONS & MODIFYING MICROBIOTA - The invention relates to methods, uses, systems, arrays, engineered nucleotide sequences and vectors for inhibiting bacterial population growth or for altering the relative ratio of sub-populations of first and second bacteria in a mixed population of bacteria. The invention is particularly useful, for example, for treatment of microbes such as for environmental, medical, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system. | 2022-08-04 |
| 20220241319 | BIOLOGICAL POLYSACCHARIDE HAVING EFFECT OF PREVENTING AND TREATING HORMONE-DEPENDENT DERMATITIS AND APPLICATION THEREOF - A composition contains β-glucan and is used for preventing and/or treating hormone-dependent dermatitis, skin mucositis or other skin inflammatory diseases. | 2022-08-04 |
| 20220241320 | MODULATORS OF IRF4 EXPRESSION - The present embodiments provide methods, compounds, and compositions useful for inhibiting IRF4 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with IRF4. | 2022-08-04 |
| 20220241321 | DIMERIC CPG OLIGONUCLEOTIDES FOR USE IN MODULATING IMMUNE RESPONSES - Pharmaceutical compositions comprising a CpG oligonucleotide, a buffer agent, and one or more salts having a total salt concentration of about 80-130 mM. A majority population of the CpG oligonucleotides in the composition is in dimeric form. Also provided herein are uses of the pharmaceutical compositions for modulating immune responses in subjects in need of the treatment, for example, cancer patient. | 2022-08-04 |
| 20220241322 | WOUND-TREATING GAS COMPOSITION, AND WOUND-TREATING APPARATUS - The invention provides a wound-treating gas composition and a wound-treating apparatus usable with a novel wound-treating method making use of hydrogen sulfide. The wound-treating gas composition contains hydrogen sulfide in a proportion of 20 ppm or lower, and the wound-treating apparatus includes a cover or container to which the wound-treating gas is fed. | 2022-08-04 |
| 20220241323 | METHOD FOR THE PRODUCTION OF IODINATED PROTEINS WITH A DETERMINATED IODINE CONTENT - The present disclosure relates to the method for the production of iodinated proteins to be used as biologically active substances and can be used for preventing and treating of the iodine deficiency conditions in humans and animals, in particular, when producing food products, biologically active food supplements, medicinal agents and veterinary preparations and foodstuffs. To this end, a method for the production of iodinated proteins and/or their hydrolyzates is proposed, comprising fermentation of the source protein raw material with an inorganic iodine aqueous solution by introducing therein a buffer mixture of reagents with a reaction mixture of enzymes immobilized on semipermeable membranes or on inert supports. The invention provides for the production of proteins with a determinated iodinated tyrosine amino acid residues content. | 2022-08-04 |
| 20220241324 | THERAPEUTIC USES OF OXIDISING HYPOTONIC ACID SOLUTIONS - Methods for treating or preventing ulcers caused by Epidermolysis Bullosa (“EB”), EGFR inhibitor-induced skin toxicities, lesions caused by Hailey-Hailey Disease (“HHD”), Buruli Ulcers, and SARS-CoV-2 infections, by topically applying a hypotonic, acid oxidizing solution containing hypochlorous acid (HClO) to the affected area. | 2022-08-04 |
| 20220241325 | ANTIOXIDANT AND ANTIVIRAL COMPOSITIONS AND METHODS - Preparations of exosomes and/or Purified Exosome Product (PEP) include antioxidant proteins and antiviral proteins. Compositions that include exosomes and/or PEP can be used to treat subject having, or at risk of having, a condition or tissue damage caused, at least in part, by oxidative stress. Also, compositions that include exosomes and/or PEP can be used to treat subject having, or at risk of having, a viral infection. | 2022-08-04 |
| 20220241326 | COMPOSITIONS AND METHODS FOR PROVIDING CHEMOPROTECTIVE EFFECTS - The disclosure relates to compositions and methods for providing chemoprotective effects to target cells. | 2022-08-04 |
| 20220241327 | Chimeric Antigen Receptor (CAR) Targeting Multiple Antigens, Compositions and Methods of Use Thereof - The present disclosure relates to compositions and methods relating to chimeric antigen receptor (CAR) polypeptides and methods relating thereto. In one embodiment, the present disclosure relates to engineered cells having chimeric antigen receptor polypeptides directed to at least two targets. In another embodiment, the present disclosure relates to engineered cells having chimeric antigen receptor polypeptides and an enhancer moiety. | 2022-08-04 |
| 20220241328 | USE OF CD8-TARGETED VIRAL VECTORS - Provided herein are methods of transducing resting or non-activated T cells using CD8-targeted viral vectors. | 2022-08-04 |
